DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Other Events

ME Staff 8-k
-
0

DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Other Events
Item 8.01 Other Events

On January9, 2018, Depomed,Inc., a California corporation (the “Company”) consummated the transactions contemplated by the Commercialization Agreement, dated as of December4, 2017, by and among the Company, Collegium Pharmaceutical, Inc., a Virginia corporation (“Collegium”), and Collegium NF, LLC, a Delaware limited liability company and wholly owned subsidiary of Collegium (the “Commercialization Agreement”). to the Commercialization Agreement, the Company granted Collegium rights to commercialize NUCYNTA® Extended Release and NUCYNTA® Immediate Release, including certain generics authorized by the Company and line extensions (collectively, “NUCYNTA”). At the closing, the parties entered into an amendment of the Commercialization Agreement.

Upon the consummation of the Commercialization Agreement, the Company received an upfront cash payment of $10,000,000 from Collegium. During the term of the Commercialization Agreement, the Company will receive royalties on all NUCYNTA revenues based on achievement of certain net sales thresholds. The Company is guaranteed minimum royalty payments through December31, 2021, and thereafter will continue to receive royalties on NUCYNTA revenues, so long as no third party has initiated wholesale or retail sales of generic versions of the products.

The description of the Commercialization Agreement and its contemplated transactions is set forth in the Company’s Current Report on Form8-K filed on December4, 2017 and is qualified in its entirety by the full text of the Commercialization Agreement and the amendment thereto, which the Company expects to file as exhibits to its Annual Report on Form10-K for the year ended December 31, 2017.

* * *


About DEPOMED,INC. (NASDAQ:DEPO)

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.